Bruce Rowlands has held the position of Chairman since May 2018 and a director of XORTX Pharma Corp., the Company’s predecessor since 2014. Bruce is the former Chairman and CEO of Eurocontrol Technics Group Inc., a TSX Venture Exchange listed company. Prior to forming Eurocontrol, Bruce worked in the biotechnology and investment banking industries as Senior Vice President with Lorus Therapeutics, Inc. a leading Canadian biotechnology company and Vice President and Director of Dominick and Dominick Securities Canada, a Canadian investment banking firm.
Bruce Cousins b comm, ca
Bruce Cousins is an accomplished biopharma industry senior finance and operations executive with experience spanning small, early stage growth to large, international companies. His prior positions in the biopharma industry include former Executive Vice President and Chief Financial Officer for both Arbutus Biopharma Corporation, a Nasdaq listed biotech company and Aspreva Pharmaceutical Inc. and Worldwide Finance Director and Worldwide Operations Controller, Johnson & Johnson. Bruce has significant public company experience, both TSX and Nasdaq as well as extensive financing and M&A experience. He holds a Honours, Bachelor of Commerce from McMaster University and he is a Chartered Accountant with the Institute of Chartered Accountants of Ontario.
Dr. Allen W. Davidoff phd
Dr. Allen W. Davidoff, Ph.D. (15 years drug development ), Formerly, Chief Scientific officer, VP Product Development and co-founder of Stem Cell Therapeutics Corp. (7 yrs) ( Trillium TRIL:NASDAQ). Prior to Stem Cell Therapeutics Corp., Senior Scientist and Head of Pharmacology at Cardiome Pharma Corp. Allen has a broad range of clinical and regulatory experience. Senior management experience in pharmaceutical R&D including 2 investigational new drug (“IND”) applications or supplemental IND’s, 2 phase I studies (4 multi-country), 7 phase II studies, and 1 NDA. 12 years C- level leadership as Co-founder of Stem Cell Therapeutics Corp (Trillium Therapeutics) – A NASDAQ listed Company and XORTX Therapeutic Corp (XRX-CSE)
Paul Van Damme b comm, cpa, mba
Paul Van Damme has held senior positions with a number of Canadian and US public companies. His experience focused on the biotech industry in Toronto when he joined GlycoDesign, a private biotech company. While at Allelix Pharmaceuticals Inc., he participated in the sale of that company to NPS Pharmaceuticals, Inc. Paul is Managing Director, WCM Capital, a Director of OncoQuest Inc. and Chief Financial Officer for Structural Genomics Consortium, a UK-based charity. He holds a B.Comm. from the University of Toronto and a MBA from the Rotman School of Management. A Chartered Professional Accountant who worked for PricewaterhouseCoopers in its Toronto and London, UK offices, he has also been appointed Chair of the XORTX Audit Committee.
Allan Williams, an independent businessman, brings over 30 years capital market and public company experience to the XORTX board. During his extensive career in the mining industry and more recently the entertainment community, Allan has been instrumental in raising over $250 million in project capital. He also has extensive mergers and acquisitions experience, most recently relating to the acquisition of Calico Resources Corp., a TSX Venture listed company by Paramount Gold Nevada Corp., a New York Stock Exchange listed company. Alan is a current director of Greatbanks Resources Inc., Maritime Resources Corp., both TSX Venture listed companies and True Grit Resources Inc., a NEX listed company.